Meluzio Michael Vincent
Known title: VP, Prin. Accounting OfficerCIK: 0002138368
Associated companies
Transaction History
| CUE | ▲ Buy | Option Exercise | 13,647 | $0 | 8/13/2026 | View on chart |
| CUE | ▼ Sell | Open Market | 1,519 | $45K | 8/13/2026 | View on chart |
| CUE | ▼ Sell | Open Market | 4,106 | $125K | 8/13/2026 | View on chart |
| CUE | ▼ Sell | Open Market | 3 | $93 | 8/13/2026 | View on chart |
| CUE | ▲ Buy | Grant | 40,942 | $0 | 7/9/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Cue Biopharma CUE-221 Meets Phase II Goals for Hives
Cue Biopharma reported that its drug CUE-221 met Phase II goals in chronic spontaneous urticaria, showing durable responses. The news highlights potential for longer-lasting relief compared to current treatments. Despite positive results, the stock has experienced an unwarranted slide, though it remains well below the average analyst target.
Cue Biopharma CUE-221 Meets Phase II Goals for Hives. Cue Biopharma reported that its drug CUE-221 met Phase II goals in chronic spontaneous urticaria, showing durable responses. The news highlights potential for longer-lasting relief compared to current treatments. Despite positive results, the stock has experienced an unwarranted slide, though it remains well below the average analyst target.